Risperdal Settlement Shows False Claims Act Prosecutions Still Have Teeth After Caronia
This article was originally published in RPM Report
Executive Summary
A $2.2 billion settlement prompts another round of headlines about the pharmaceutical industry's marketing practices -- and no apparent indication that the Caronia ruling is changing the way prosecutors (and the public) perceive off-label promotion.
You may also be interested in...
Digesting Caronia
A December appellate court ruling in an off-label promotion case prompted headlines about sweeping implications for FDA’s regulatory authority. How does the ruling look four months later?
GSK’s DoJ Settlement Links Executive Bonus To Continued Compliance
GlaxoSmithKline pleads guilty to marketing Paxil and Wellbutrin off-label and concealing Avandia safety data from FDA and resolves allegations of kickbacks involving nine drugs; ground-breaking corporate integrity agreement includes novel recoup of bonuses from execs if they or their subordinates engage in “significant misconduct.”
Bextra Settlement Coming Soon: Industry Should Brace for Impact
Record setting $2.3 billion payment is afterthought in context of Pfizer/Wyeth merger, but the Bextra and recent Zyprexa settlement will have far-reaching implications. In economic terms, the first two cases of 2009 exceed the total recoveries of the last 13 pharma marketing settlements. But the big impact may be political: the cases involve a volatile mix of marketing abuses and drug safety